Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Anastomoses01:19

Anastomoses

In human anatomy, anastomosis refers to a connection or opening between two things, particularly between blood vessels or other tubular structures. The term is derived from the Greek term 'anastomosis,' which means 'outlet' or 'opening.' This natural network of connections plays a critical role in the survival and functionality of the human body.
Anastomoses can be formed at arterial, venous, and lymphatic vessels.
Arterial Anastomosis: These occur between arteries. They are most common in...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Vascular Spasm01:16

Vascular Spasm

The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last for...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating a nurse-led, audit-based antimicrobial stewardship in the medical emergency unit of a tertiary level hospital.

Infection control and hospital epidemiology·2026
Same author

A Pilot Randomized Controlled Trial Comparing the Efficacy and Safety of Oral Tofacitinib Versus Methotrexate In Moderate-to-Severe Alopecia Areata.

Indian dermatology online journal·2026
Same author

Recalibration of the European Kidney Function Consortium eGFR Equation for the Indian Population.

Kidney international reports·2026
Same author

Retraction notice to 'Hispolon: A natural polyphenol and emerging cancer killer by multiple cellular signaling pathways' [Environ. Res. 190 (2020) 110017].

Environmental research·2026
Same author

Novel Azo-Oxazine-Tetrazole Hybrids Conjugated with TEMPO-oxidized Cellulose Nanocrystals: Synthesis, Antibacterial Evaluation, and Molecular Docking Against Drug-resistant S. aureus.

Current organic synthesis·2026
Same author

Identification and Characterization of New Therapeutic Candidates for Naegleria fowleri- brain-eating Amoeba: A Multi-target Approach Based on 3D-QSAR, Molecular Docking, MM-GBSA, ADMET and Molecular Dynamics.

Combinatorial chemistry & high throughput screening·2026

Related Experiment Video

Updated: Jul 18, 2026

4D Printed Bifurcated Stents with Kirigami-Inspired Structures
06:52

4D Printed Bifurcated Stents with Kirigami-Inspired Structures

Published on: July 25, 2019

Cypher versus Taxus: the stent war.

Nusrat Shafiq1, Samir Malhotra, Promila Pandhi

  • 1Postgraduate Institute of Medical Education and Research, Department of Pharmacology, Chandigarh, 160012, India.

Expert Opinion on Investigational Drugs
|November 17, 2006
PubMed
Summary

The Cypher and Taxus drug-eluting stents improve outcomes in coronary artery disease compared to bare metal stents. Head-to-head trials compare their effectiveness in various lesion types.

Related Experiment Videos

Last Updated: Jul 18, 2026

4D Printed Bifurcated Stents with Kirigami-Inspired Structures
06:52

4D Printed Bifurcated Stents with Kirigami-Inspired Structures

Published on: July 25, 2019

Area of Science:

  • Interventional Cardiology
  • Biomedical Engineering
  • Pharmacology

Background:

  • Drug-eluting stents (DES) like Cypher (sirolimus) and Taxus (paclitaxel) are FDA-approved for percutaneous coronary intervention.
  • Both DES have demonstrated superiority over bare metal stents in reducing major adverse cardiac events, restenosis, and target vessel revascularization.
  • Recent clinical trials have provided head-to-head comparisons of Cypher and Taxus stent performance.

Purpose of the Study:

  • To compare the clinical performance of Cypher and Taxus drug-eluting stents.
  • To evaluate stent efficacy across different types of coronary artery lesions.
  • To synthesize findings from observational studies and clinical trials.

Main Methods:

  • Systematic review of published clinical trials and observational studies.
  • Comparative analysis of patient outcomes, including major adverse cardiac events, restenosis, and target vessel revascularization.
  • Evaluation of stent performance based on lesion characteristics.

Main Results:

  • Both Cypher and Taxus stents significantly reduce adverse cardiac events compared to bare metal stents.
  • Head-to-head comparisons show varying degrees of efficacy depending on lesion complexity and specific endpoints.
  • Long-term data suggests potential differences in safety and effectiveness profiles between the two DES.

Conclusions:

  • Cypher and Taxus stents represent significant advancements in treating obstructive coronary artery disease.
  • The choice between Cypher and Taxus may depend on patient-specific factors and lesion characteristics.
  • Further research is warranted to fully elucidate long-term outcomes and optimal stent selection.